CHARLOTTE, N.C., Feb. 10 /PRNewswire/ -- USHIFU, a worldwide leader in the development, distribution and use of minimally invasive high intensity focused ultrasound technologies, is pleased to announce the appointment of Mark Schoenberg, M.D. to the consulting position of Chief Medical Officer. Dr. Schoenberg is an internationally recognized expert in the area of Urologic Oncology who has authored more than 100 peer-reviewed publications and has 15 years experience as a clinical investigator.
Dr. Schoenberg will assist the company in its current effort to complete critical clinical trials with the Sonablate(R) 500 technology in the treatment of patients with prostate cancer. Additionally, he will spearhead a scholarly effort to critically evaluate current clinical experiences with HIFU therapy in collaboration with the Sonablate(R) International HIFU Registry.
Dr. Schoenberg will help USHIFU create educational materials describing the use of HIFU technology and will assist in developing a series of initiatives for the treatment of other malignancies. Dr. Schoenberg has an active clinical practice and serves as a Professor of Urology at Johns Hopkins University.
Steve Puckett, Jr., USHIFU CEO said, “We are thrilled to announce the addition of Dr. Mark Schoenberg to the USHIFU team as Chief Medical Officer of our company. I’ve had the privilege of working with Dr. Schoenberg on a consulting basis over the past several months and his contributions towards our clinical trial research and academic relationships have been extremely valuable. We look forward to leveraging Dr. Schoenberg’s unique skill set as we continue to build a world class healthcare organization.”
About USHIFU, LLC
USHIFU, based in Charlotte, NC, is a worldwide leader in the development, distribution and use of minimally invasive high intensity focused ultrasound technologies. Dr. Schoenberg holds no equity in USHIFU.
About the Sonablate(R) 500
The Sonablate(R) 500 is a minimally invasive medical device that utilizes ultrasound energy to destroy tissue within the body. It was developed by FSI and is manufactured by Misonix, Inc. who also holds distribution rights in Europe. Takai Hospital Supply Ltd. and THS International distribute the Sonablate(R) 500 in Southeast Asia and the Middle East.
The Sonablate(R) 500 is not approved for use in the U.S. The Sonablate(R) 500 remains investigational in the U.S. and is being studied for the treatment of prostate cancer in clinical trials in the U.S. FDA has made no decision as to the safety or efficacy of the Sonablate(R) 500 for the treatment of prostate cancer.
CONTACT: Amanda Willis of USHIFU, +1-704-936-1823, amandawillis@ushifu.com
Web site: http://www.internationalhifu.com/
